Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sen. McCaskill Reaches Out To Retailers On Picamilon ‘In The Absence Of FDA Action’

This article was originally published in The Tan Sheet

Executive Summary

The Missouri Democrat tells retailers that FDA “hasn’t lifted a finger to inform the public or taken any action to remove” picamilon. Although an FDA official said in an affidavit to the Oregon AG that picamilon is not a dietary ingredient, the agency has not warned firms or consumers that it is unsafe.

You may also be interested in...

Supplements For Disease-Related Nutrition Shaping Consumer Health Landscape

Sales of dietary supplements promoted for nutritional needs of diabetics are exploding as consumers seek non-drug products to deal with symptoms of the disease, says a consumer health analyst in a recent presentation. Consumer health products positioned to prevent disease are growing at a much faster rate globally than those formulas that treat ailments.

GAO Memory Supplement Review Recalls FDA's Regulatory Challenges

GAO recommends better cooperation between FDA and FTC and more public outreach are key to preventing consumers from believing noncompliant cognitive benefit claims for supplements.

GOP Request To Stall New Rules: Post-Election Business As Usual On Capitol Hill

House Republican leaders' request that federal agencies halt rulemaking until Trump's inauguration was not unexpected and their request tracks with the president-elect's priority for trimming regulations. "I think it was really a move to stop the administration from trying to legislate by fiat," says NPA chief Daniel Fabricant.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts